393 related articles for article (PubMed ID: 31729990)
1. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.
Pratley RE; Husain M; Lingvay I; Pieber TR; Mark T; Saevereid HA; Møller DV; Zinman B;
Cardiovasc Diabetol; 2019 Nov; 18(1):156. PubMed ID: 31729990
[TBL] [Abstract][Full Text] [Related]
2. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial.
Wysham C; Bhargava A; Chaykin L; de la Rosa R; Handelsman Y; Troelsen LN; Kvist K; Norwood P
JAMA; 2017 Jul; 318(1):45-56. PubMed ID: 28672317
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
[TBL] [Abstract][Full Text] [Related]
4. Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.
Lane W; Bailey TS; Gerety G; Gumprecht J; Philis-Tsimikas A; Hansen CT; Nielsen TSS; Warren M; ;
JAMA; 2017 Jul; 318(1):33-44. PubMed ID: 28672316
[TBL] [Abstract][Full Text] [Related]
5. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
Pollock RF; Heller S; Pieber TR; Woo V; Gundgaard J; Hallén N; Luckevich M; Tutkunkardas D; Zinman B;
Diabetes Obes Metab; 2019 Jul; 21(7):1706-1714. PubMed ID: 30924579
[TBL] [Abstract][Full Text] [Related]
6. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7).
Pratley RE; Emerson SS; Franek E; Gilbert MP; Marso SP; McGuire DK; Pieber TR; Zinman B; Hansen CT; Hansen MV; Mark T; Moses AC; Buse JB;
Diabetes Obes Metab; 2019 Jul; 21(7):1625-1633. PubMed ID: 30850995
[TBL] [Abstract][Full Text] [Related]
8. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2).
Zinman B; Marso SP; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Lange M; Brown-Frandsen K; Moses A; Ocampo Francisco AM; Barner Lekdorf J; Kvist K; Buse JB;
Diabetologia; 2018 Jan; 61(1):48-57. PubMed ID: 28913575
[TBL] [Abstract][Full Text] [Related]
9. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality.
Pieber TR; Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pratley RE; Woo V; Heller S; Lange M; Brown-Frandsen K; Moses A; Barner Lekdorf J; Lehmann L; Kvist K; Buse JB;
Diabetologia; 2018 Jan; 61(1):58-65. PubMed ID: 28913543
[TBL] [Abstract][Full Text] [Related]
10. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1.
Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Frandsen KB; Rabøl R; Buse JB
Am Heart J; 2016 Sep; 179():175-83. PubMed ID: 27595693
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for kidney disorders in patients with type 2 diabetes at high cardiovascular risk: An exploratory analysis (DEVOTE 12).
Amod A; Buse JB; McGuire DK; Pieber TR; Pop-Busui R; Pratley RE; Zinman B; Hansen MB; Jia T; Mark T; Poulter NR;
Diab Vasc Dis Res; 2020; 17(6):1479164120970933. PubMed ID: 33280425
[TBL] [Abstract][Full Text] [Related]
12. Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial.
Tarride JE; Husain M; Andersen A; Gundgaard J; Luckevich M; Mark T; Wagner L; Pieber TR
J Med Econ; 2021; 24(1):1318-1326. PubMed ID: 34763587
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial.
Bilal A; Pratley RE
Curr Diab Rep; 2018 Sep; 18(11):102. PubMed ID: 30229352
[TBL] [Abstract][Full Text] [Related]
14. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
Pollock RF; Valentine WJ; Marso SP; Andersen A; Gundgaard J; Hallén N; Tutkunkardas D; Magnuson EA; Buse JB;
Appl Health Econ Health Policy; 2019 Oct; 17(5):615-627. PubMed ID: 31264138
[TBL] [Abstract][Full Text] [Related]
15. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials.
Zhang XW; Zhang XL; Xu B; Kang LN
Acta Diabetol; 2018 May; 55(5):429-441. PubMed ID: 29423761
[TBL] [Abstract][Full Text] [Related]
16. Day-to-day fasting self-monitored blood glucose variability is associated with risk of hypoglycaemia in insulin-treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials.
DeVries JH; Bailey TS; Bhargava A; Gerety G; Gumprecht J; Heller S; Lane W; Wysham CH; Zinman B; Bak BA; Hachmann-Nielsen E; Philis-Tsimikas A
Diabetes Obes Metab; 2019 Mar; 21(3):622-630. PubMed ID: 30362250
[TBL] [Abstract][Full Text] [Related]
17. Developing, Planning and Conducting an Interim Analysis: Lessons From the DEVOTE Cardiovascular Outcomes Trial (Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events).
Theilgaard H; Mollerup I; Helmark IC; Endahl L; Hoskin S; Hvelplund A; Amby LK; Moses AC
Ther Innov Regul Sci; 2019 Mar; 53(2):279-286. PubMed ID: 29793353
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Russel-Szymczyk M; Valov V; Savova A; Manova M
BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
[TBL] [Abstract][Full Text] [Related]
20. Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100.
Alexopoulos AS; Andersen A; Donatsky AM; Gowda A; Buse JB
Diabetes Obes Metab; 2021 Aug; 23(8):1983-1988. PubMed ID: 33830626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]